Vanguard Global Advisers
KURA icon

Vanguard Global Advisers’s Kura Oncology KURA Stock Holding History

Vanguard Global Advisers’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$366K Sell
33,380
-9,058
-21% -$85.5K ﹤0.01% 2249
2026
Q1 		$345K Buy
+42,438
New +$365K ﹤0.01% 2194

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Vanguard Global Advisers's KURA Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Kura Oncology (KURA) stake by 21% in Q2 2026, selling an estimated $85.5K and leaving 33,380 shares worth $366K. The position accounts for ﹤0.01% of the portfolio, ranked #2249.

Vanguard Global Advisers first reported a position in KURA in Q1 2026 and has held it in 2 quarters since. 219 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

  • Vanguard Global Advisers held 33,380 shares of Kura Oncology worth $366K as of Q2 2026.
  • Vanguard Global Advisers sold 9,058 Kura Oncology shares in Q2 2026, an estimated $85.5K.
  • Kura Oncology made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2249 holding.
  • Vanguard Global Advisers first reported a position in Kura Oncology in Q1 2026 and has held it in 2 quarters since.
  • 219 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.